Publications & posters

SIRS 2025: Insights on Schizophrenia Research, From Rights Based Care to Digital Biomarkers Michael Spilka, Sr. Clinical Scientist This year’s Schizophrenia International Research Society (SIRS) 2025 Congress in Chicago brought together leading scientists and researchers, exploring the latest advancements and ongoing challenges in understanding and addressing schizophrenia. Michael Spilka, PhD. shares his key insights from […]

Spin-out Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board Thursday 17th April Manchester, UK, 17 April 2024 – Monument Therapeutics, a precision, neuroscience company focused on the development of innovative treatments forserious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has

Dementias Platform UK: TRANSLATION 2025 Martina De Lillo, Clinical Scientist We recently attended TRANSLATION 2025, organized by Dementia Platform UK, where experts shared groundbreaking developments in treatment approaches, diagnostic methods, and research methodologies. The presentations revealed a field undergoing rapid transformation, with significant implications for patients and healthcare professionals alike. The theme of the conference

When to Use Standardised Assessments—And When You Might Need to Build Your Own Alex Kaula, Senior R&D Scientist Hello, I’m Alex Kaula, Senior R&D Scientist at Cambridge Cognition. If your research involves measuring cognitive function or clinical outcomes, you’ve likely faced this question: Should I use an established, validated assessment, or create a new one

Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial 10 April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical

Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions 3rd April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase

Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions 3rd April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase